The WACC of Kilitch Drugs (India) Ltd (KILITCH.NS) is 15.4%.
| Range | Selected | |
| Cost of equity | 14.30% - 17.20% | 15.75% |
| Tax rate | 29.00% - 30.30% | 29.65% |
| Cost of debt | 7.80% - 12.90% | 10.35% |
| WACC | 13.9% - 16.8% | 15.4% |
| Category | Low | High |
| Long-term bond rate | 6.9% | 7.4% |
| Equity market risk premium | 8.3% | 9.3% |
| Adjusted beta | 0.89 | 1 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 14.30% | 17.20% |
| Tax rate | 29.00% | 30.30% |
| Debt/Equity ratio | 0.05 | 0.05 |
| Cost of debt | 7.80% | 12.90% |
| After-tax WACC | 13.9% | 16.8% |
| Selected WACC | 15.4% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for KILITCH.NS:
cost_of_equity (15.75%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (0.89) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.